A 385358

CAS No. 406228-55-5

A 385358( A385358 )

Catalog No. M14400 CAS No. 406228-55-5

A 385358 is a potent, selective, cell-permeable Bcl-XL inhibitor with Ki of 0.8 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 176 Get Quote
10MG 266 Get Quote
25MG 461 Get Quote
50MG 669 Get Quote
100MG 945 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    A 385358
  • Note
    Research use only, not for human use.
  • Brief Description
    A 385358 is a potent, selective, cell-permeable Bcl-XL inhibitor with Ki of 0.8 nM.
  • Description
    A 385358 is a potent, selective, cell-permeable Bcl-XL inhibitor with Ki of 0.8 nM, displays >80-fold selectivity over Bcl-2 (Ki=64 nM); shows relatively modest single-agent cytotoxic activity against most tumor cell lines with an EC50 of <500 nM in cells dependent on Bcl-X(L) for survival; enhances the in vitro cytotoxic activity of numerous chemotherapeutic agents; significantly inhibits tumor growth in the A549 xenograft model.
  • In Vitro
    A-385358 is a selective inhibitor of Bcl-XL with Kis of 0.80 and 67 nM for Bcl-XL and Bcl-2, respectively, in fluorescence polarization assays. Treatment of IL-3-deprived FL5.12/Bcl-XL cells for 24 hours with A-385358 results in cell killing with an EC50 of 0.47±0.05 μM (n=68). This effect is accompanied by an increase in caspase-3 activity. Consistent with the greater affinity for the Bcl-XL versus Bcl-2 hydrophobic grooves, the EC50 of A-385358 for IL-3-depleted FL5.12/Bcl-2 cells (1.9±0.1 μM; n=55) is 4-fold higher relative to the cytokine-deprived FL5.12/Bcl-XL cells. In addition, A-385358 is more effective at stimulating cytochrome c release from mitochondria isolated from FL5.12/Bcl-XL versus Bcl-2 cells.
  • In Vivo
    The combination of A-385358 given at 100 mg/kg/d plus the lower dose of paclitaxel produces a significant reduction in tumor growth (%T/C) compare with paclitaxel monotherapy. This combination also yields a >100% increase in time for tumors to reach 900 mm3 (%ILS) compare with vehicle control. Maximal efficacy is observed during the dosing period for A-385358, with slow but steady increase in the tumor growth after termination of treatment. The combination of A-385358 at 75 mg/kg/d plus paclitaxel at 30 mg/kg/d is also well tolerated and inhibits tumor growth rate by nearly 80%. Significant effects on tumor growth relative to paclitaxel monotherapy are observed with doses as low as 50 mg/kg/d.
  • Synonyms
    A385358
  • Pathway
    Angiogenesis
  • Target
    Bcl-2
  • Recptor
    Bcl-2
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    406228-55-5
  • Formula Weight
    639.83
  • Molecular Formula
    C32H41N5O5S2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : 125 mg/mL195.36 mM
  • SMILES
    O=C(NS(=O)(C1=CC=C(N[C@H](CCN(C)C)CSC2=CC=CC=C2)C([N+]([O-])=O)=C1)=O)C3=CC=C(N4CCC(C)(C)CC4)C=C3
  • Chemical Name
    N-[4-[[(2R)-4-(Dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-(4,4-dimethylpiperidin-1-yl)benzamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Wendt MD, et al. J Med Chem. 2006 Feb 9;49(3):1165-81. 2. Shoemaker AR, et al. Cancer Res. 2006 Sep 1;66(17):8731-9.
molnova catalog
related products
  • Chelerythrine chlori...

    Chelerythrine chloride is a potent, cell-permeable inhibitor of PKC (IC50=66 nM) and p38 MAPK.

  • AZD 5991

    AZD 5991 (AZD5991) is a potent and selective macrocyclic inhibitor of Mcl-1 with sub-nanomolar affinity.

  • Paederosidic acid

    Paederosidic acid has significant anti-tumor anticonvulsant and sedative effects. Paederosidic acid increases brain gamma-aminobutyric acid and decreases glutamic acid in the brain and it up-regulates expressions of GAD 65 may be a promising future therapeutic agent for treatment of epilepsy.